Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SULT2A1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SULT2A1 Recombinant Protein / Mutant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View SULT2A1 Products |
| Gene Delivery | SULT2A1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View SULT2A1 Products |
| Benchmark Ab | Anti-SULT2A1 Recombinant Antibody Recombinant positive control for assay validation. |
View SULT2A1 Products |
| Validator | SULT2A1 siRNA Set For knockdown verification in functional assays. |
View SULT2A1 Products |
| Related Target A | SULT1A1 Critical for selectivity screening to avoid off-target sulfotransferase activity. |
View SULT1A1 Products |
| Related Target B | SULT2B1 Subfamily homolog; essential for profiling lipid and cholesterol sulfation selectivity. |
View SULT2B1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Cross-Reactivity | SULT1A1, SULT1E1, and SULT2B1 panel proteins available with >95% purity for counter-screening. |
| Polymorphic Variant Profiling | Custom mutant recombinant proteins designed based on theoretical MW and sequence verification. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included |
| False Positives | Validated siRNA pool included for target specificity and knockdown verification |
Live SULT2A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SULT2A1 therapeutics is intensifying, with major players shifting focus from traditional endocrine models to metabolic dysfunction-associated steatohepatitis (MASH/NASH) and castration-resistant prostate cancer (CRPC). As first-generation small molecule modulators reach preclinical validation, the next wave of R&D is targeting highly selective SULT2A1 inhibitors to block androgen synthesis or modulators to regulate bile acid homeostasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic & Biotech Consortia | Prostate Cancer, Adrenocortical Carcinoma | Enzymatic Selectivity Assay (Need High-Purity SULT family panel proteins) |
| Small Molecule Activators | Hepatology Specialists | Cholestasis, MASH / NASH | Bile Acid Sulfation Assays (Need Sequence-Verified WT SULT2A1) |
| RNA Therapeutics | Gene Therapy Biotechs | Metabolic Disorders | Target Knockdown Validation (Need High-Titer Lentivirus & Validated siRNA) |